Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). [electronic resource]
Producer: 20191011ISSN:- 1946-6242
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Bortezomib -- pharmacology
- Cell Line, Tumor
- Cyclin-Dependent Kinase Inhibitor p21 -- genetics
- DNA Damage
- DNA Methylation -- genetics
- Decitabine -- pharmacology
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- Gene Expression Regulation, Neoplastic -- drug effects
- Genes, Tumor Suppressor
- High-Throughput Screening Assays
- Humans
- Mice
- Mitomycin -- pharmacology
- Multiple Myeloma -- drug therapy
- Phenotype
- Protein Tyrosine Phosphatase, Non-Receptor Type 6 -- genetics
- RNA, Messenger -- genetics
- Tumor Burden -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.